Your browser is no longer supported. Please, upgrade your browser.
DARE [NASD]
Dare Bioscience, Inc.
Index- P/E- EPS (ttm)-0.91 Insider Own5.81% Shs Outstand47.31M Perf Week-6.06%
Market Cap56.16M Forward P/E- EPS next Y-0.70 Insider Trans0.00% Shs Float45.66M Perf Month-17.33%
Income-27.40M PEG- EPS next Q-0.22 Inst Own10.60% Short Float2.54% Perf Quarter-48.12%
Sales- P/S- EPS this Y5.70% Inst Trans0.65% Short Ratio1.13 Perf Half Y18.10%
Book/sh-0.03 P/B- EPS next Y10.30% ROA-322.50% Target Price- Perf Year18.10%
Cash/sh0.10 P/C11.95 EPS next 5Y- ROE- 52W Range0.91 - 3.85 Perf YTD-7.46%
Dividend- P/FCF- EPS past 5Y43.30% ROI- 52W High-67.79% Beta1.82
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin- 52W Low36.26% ATR0.09
Employees23 Current Ratio0.90 Sales Q/Q- Oper. Margin- RSI (14)30.19 Volatility7.37% 6.59%
OptionableNo Debt/Eq- EPS Q/Q-3.10% Profit Margin- Rel Volume0.60 Prev Close1.27
ShortableYes LT Debt/Eq- EarningsMay 13 AMC Payout- Avg Volume1.03M Price1.24
Recom2.00 SMA20-13.01% SMA50-26.07% SMA200-15.13% Volume611,294 Change-2.36%
May-13-21 02:30PM  
08:00AM  
May-06-21 08:00AM  
Apr-27-21 08:00AM  
Apr-26-21 08:00AM  
Apr-19-21 08:00AM  
Mar-30-21 02:30PM  
08:00AM  
Mar-24-21 08:00AM  
Mar-23-21 08:00AM  
Mar-22-21 08:00AM  
Mar-10-21 08:00AM  
Mar-08-21 08:00AM  
Mar-02-21 08:00AM  
Feb-25-21 08:00AM  
Feb-16-21 08:00AM  
Feb-09-21 08:00AM  
Jan-05-21 08:00AM  
Dec-22-20 01:23AM  
Dec-07-20 08:00AM  
Nov-12-20 02:30PM  
08:00AM  
Nov-05-20 08:00AM  
Oct-07-20 08:00AM  
Sep-21-20 08:00AM  
Sep-08-20 08:00AM  
Sep-01-20 08:04AM  
Aug-20-20 08:00AM  
Aug-19-20 08:00AM  
Aug-12-20 08:00AM  
Aug-06-20 08:00AM  
Aug-05-20 08:00AM  
Jul-27-20 08:00AM  
Jul-13-20 07:02PM  
Jun-17-20 08:00AM  
Jun-15-20 08:00AM  
Jun-04-20 08:00AM  
May-17-20 03:02PM  
May-14-20 08:00AM  
May-11-20 08:00AM  
May-07-20 08:00AM  
Apr-28-20 08:00AM  
Apr-23-20 08:00AM  
Apr-08-20 04:24PM  
Apr-01-20 08:00AM  
Mar-30-20 02:30PM  
08:00AM  
Mar-29-20 09:45AM  
Mar-24-20 08:00AM  
Mar-10-20 08:00AM  
Mar-09-20 08:00AM  
Feb-27-20 08:00AM  
Feb-12-20 04:05PM  
Feb-06-20 08:00AM  
Feb-05-20 08:00AM  
Jan-30-20 08:00AM  
Jan-22-20 06:55AM  
Jan-17-20 12:19PM  
Jan-15-20 08:00AM  
Jan-13-20 07:00AM  
Dec-18-19 08:00AM  
Dec-11-19 08:00AM  
Dec-10-19 08:00AM  
Dec-09-19 07:15AM  
Dec-04-19 03:43PM  
Nov-21-19 08:00AM  
Nov-14-19 08:07AM  
08:00AM  
Nov-12-19 08:00AM  
Nov-11-19 08:00AM  
Nov-07-19 08:30AM  
Oct-31-19 08:00AM  
Oct-28-19 08:00AM  
Oct-24-19 08:00AM  
Oct-14-19 08:00AM  
Oct-10-19 08:00AM  
Oct-07-19 08:00AM  
Sep-13-19 02:04PM  
Sep-11-19 08:00AM  
Sep-09-19 12:13PM  
08:00AM  
Sep-04-19 08:00AM  
Aug-14-19 04:01PM  
Aug-12-19 01:59PM  
08:00AM  
Aug-08-19 08:00AM  
Aug-06-19 08:00AM  
Jul-22-19 08:00AM  
Jul-17-19 08:00AM  
Jul-15-19 08:00AM  
Jul-11-19 03:51PM  
Jun-26-19 08:00AM  
Jun-17-19 08:00AM  
May-29-19 08:00AM  
May-28-19 03:00PM  
11:22AM  
May-14-19 04:00PM  
May-08-19 08:00AM  
May-07-19 08:00AM  
Apr-15-19 10:26AM  
Dare Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.